Navigation Links
ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
Date:10/30/2010

luded as well as interim SVR rates based on data available to date; and (v) the beneficial effect of ANA598 in both CC and non-CC patients based on observations in the Phase II combination study. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2009, Form 10-Q for the quarter ended September 30, 2010 and Form 8-K filed on October 15, 2010. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Pegasys® and Copegus® are registered trademarks of Ho
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... "Global Hypodermic Needles Market 2014-2018" report to their ... A hypodermic needle is a hollow needle commonly ... body or or to extract fluids from it. A ... or to inject substances that cannot be ingested. Hypodermic ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
(Date:7/12/2014)... Warminster, PA (PRWEB) July 12, 2014 ... Paddock covering a variety of men’s health questions. ... issues specific to men, why women live longer than ... article, Men's Health Made Simple featured on ... can get a hernia at any age. If you ...
(Date:7/12/2014)... recent article released by Seattle's well known plastic surgeon, Dr. ... cosmetic surgical procedures in summer months . , ... to enliven the rainy Pacific Northwest, many people are turning ... work out as much during the winter as they had ... people eager to look their best for their summer vacations, ...
(Date:7/12/2014)... July 12, 2014 Floor-grade ... of 4.1 out of 5. This above-average score ... been underpinning buyer negotiation power over the three ... Anna Son, “during the period, surging demand for ... associated with new product development, have placed upward ...
(Date:7/11/2014)... MagicQuinceaneraDresses.com, the popular online supplier of special occasion gowns, ... dresses . The company’s new items are specially designed ... a large amount of money. They are all available ... company’s online shop has become a one stop platform ... addition to exquisite Quinceanera dresses, it also offers great ...
(Date:7/11/2014)... July 11, 2014 Ticket Down reports that ... and 3rd place World Cup Match between Brazil ... match will take place on Saturday, July 12th at Estadio ... Cup Finals will take place on Sunday, July 13th at ... Janiero. All tickets for the 2014 World Cup are guaranteed ...
Breaking Medicine News(10 mins):Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2
... more likely in the overweight , , MONDAY, March 3 ... than normal-weight children to have breathing-related problems during surgery, ... The researchers, who looked at 1,380 normal-weight, 351 overweight, ... had elective, non-cardiac surgery, found that obese children had ...
... N.J., March 3 Sparta Systems, Inc. ... leader in enterprise quality and,compliance management software, ... and manufacturer of sterile injectable pharmaceutical and,Medical ... critical quality,management and compliance activities., Given ...
... ,InterACTIVE Nutrition International Inc., a subsidiary of ... http://www.naturalnutritioninc.com has recently,shipped its first order ... InterACTIVE Nutrition, Inc., is able to fulfill ... in Iraq. The first,order was shipped on ...
... Members And Their Families In 29 States And Washington, ... Of Affordable Health Plans, NEW YORK, March 3 ... community of artists and arts,organizations, announced today that Aetna ... states and Washington, DC., According to the U.S. ...
... March 3 Smith & Nephew,Inc.,s (NYSE: ... Japanese regulatory approval of its award winning OXINIUM(TM),oxidized ... only orthopaedic company to offer such a,revolutionary and ... transformed metal alloy with a ceramic bearing surface. ...
... for The Leukemia & Lymphoma Society,s 2008 Light The Night ... ... Brown, who stars in the,upcoming drama The Express as Ernie Davis, a 1960s ... is the national spokesperson for The Leukemia & Lymphoma Society,s,(LLS) 2008 Light The ...
Cached Medicine News:Health News:Obese Children Face More Complications During Surgery 2Health News:Bioniche Pharma Chooses TrackWise for its Deviation Control Solution 2Health News:Natural Nutrition Ships First InterACTIVE Nutrition Brand Products to Iraq 2Health News:Fractured Atlas Offers Affordable Aetna Advantage Plans for Artists 2Health News:Fractured Atlas Offers Affordable Aetna Advantage Plans for Artists 3Health News:Smith & Nephew Wins OXINIUM(TM) Approval in Japan 2Health News:Smith & Nephew Wins OXINIUM(TM) Approval in Japan 3Health News:Actor Rob Brown Rushes to Gain Ground Against Blood Cancer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: